E-cigarette battle lines form in federal court

Last week, we highlighted the Oregon attorney general's fight against e-cigarettes, which he considers to be a drug-delivery device being sold to consumers without proper approval from the FDA. The Wall Street Journal points out that the battle goes far beyond Oregon. It is nationwide and just beginning. The industry that markets the battery-powered tubes that turn nicotine-laced liquid into into vapor claims that it is offering products "designed to be recreational alternatives to cigarettes, not devices to wean people off nicotine." If they had to go through clinical trials, they'd be out of business or forced underground. Next week, a federal appellate court hears oral arguments on the question. Report

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.